BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 11022717)

  • 21. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
    Matveev BP; Bukharkin BV
    Urologiia; 2001; (6):20-1. PubMed ID: 11785074
    [No Abstract]   [Full Text] [Related]  

  • 22. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
    Blackledge G; Kolvenbag G; Nash A
    Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antiandrogen in prostate cancer].
    Maeda O; Usami M
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
    [No Abstract]   [Full Text] [Related]  

  • 24. New molecules and treatment modulation in advanced prostatic cancer.
    Mahler C; Verhelst J; Denis L
    Acta Urol Belg; 1996 May; 64(2):95-8. PubMed ID: 8701825
    [No Abstract]   [Full Text] [Related]  

  • 25. [Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist].
    Martorana G
    Recenti Prog Med; 2002 Mar; 93(3):179-82. PubMed ID: 11942170
    [No Abstract]   [Full Text] [Related]  

  • 26. [A new anti-androgen, bicalutamide (Casodex), for the treatment of prostate cancer--basic clinical aspects].
    Akaza H
    Gan To Kagaku Ryoho; 1999 Jul; 26(8):1201-7. PubMed ID: 10431591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
    Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Unreliable survival analysis].
    Tretli S; Kvåle R; Hernes E
    Tidsskr Nor Laegeforen; 2009 Feb; 129(5):429-30; author reply 430. PubMed ID: 19247405
    [No Abstract]   [Full Text] [Related]  

  • 29. Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens.
    Ellwood-Yen K; Wongvipat J; Sawyers C
    Cancer Res; 2006 Nov; 66(21):10513-6. PubMed ID: 17079473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of male breast cancer in association with bicalutamide-induced gynaecomastia.
    Chianakwalam CI; McCahy P; Griffiths NJ
    Breast; 2005 Apr; 14(2):163-4. PubMed ID: 15767188
    [No Abstract]   [Full Text] [Related]  

  • 31. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
    Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M; Penson D
    Urology; 2005 Oct; 66(4):835-9. PubMed ID: 16230148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature.
    Arce-Salinas C; Riesco-Martinez MC; Hanna W; Bedard P; Warner E
    J Clin Oncol; 2016 Feb; 34(4):e21-4. PubMed ID: 24888812
    [No Abstract]   [Full Text] [Related]  

  • 33. Bicalutamide for prostate cancer.
    Med Lett Drugs Ther; 1996 Jun; 38(977):56-7. PubMed ID: 8657047
    [No Abstract]   [Full Text] [Related]  

  • 34. New indication sought for bicalutamide.
    Oncology (Williston Park); 2000 May; 14(5):654, 772. PubMed ID: 10853458
    [No Abstract]   [Full Text] [Related]  

  • 35. A new non-steroidal anti-androgen.
    Denis L
    Prog Clin Biol Res; 1989; 303():95-103. PubMed ID: 2675023
    [No Abstract]   [Full Text] [Related]  

  • 36. [Total androgen blockade].
    Namiki M; Mizokami A
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
    [No Abstract]   [Full Text] [Related]  

  • 37. [Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program].
    Mansueto G; Longo F
    Recenti Prog Med; 2002 Mar; 93(3):175-8. PubMed ID: 11942169
    [No Abstract]   [Full Text] [Related]  

  • 38. Structural basis for antagonism and resistance of bicalutamide in prostate cancer.
    Bohl CE; Gao W; Miller DD; Bell CE; Dalton JT
    Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6201-6. PubMed ID: 15833816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
    Akakura K; Furuya Y; Ito H
    Nihon Rinsho; 1998 Aug; 56(8):2124-8. PubMed ID: 9750520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program.
    Brawer MK
    BJU Int; 2003 Apr; 91(6):465-6. PubMed ID: 12656893
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.